1cP-MiPLA

From PsychonautWiki
Jump to navigation Jump to search
Yellow-warning-sign1.svg

This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Summary sheet: 1cP-MiPLA
1cP-MiPLA
Chemical Nomenclature
Common names 1cP-MiPLA
Substitutive name 1-Cyclopropionylmethylisoproyllysergamide
Systematic name (6aR,9R)1-Cyclopropionyl-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 50 µg
Light 100 - 150 µg
Common 150 - 200 µg
Strong 200 - 250 µg
Heavy 300 µg +
Duration
Total 4 - 6 hours
Onset 20 - 40 minutes
Come up 45 - 90 minutes
Peak 1 - 2 hours
Offset 1 - 2 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Cannabis
Stimulants
Tramadol
Lithium

1-Cyclopropionyl-N-nethyl-N-isopropyllysergamide (also known commonly as 1cP-MiPLA) is a novel psychedelic substance of the lysergamide class. 1cP-MiPLA is closely related to MiPLA, for which it is suspected to be a prodrug for, but there is currently no data or enough anecdotal reports to reasonably hypothesize this.

1cP-AL-LAD is a novel research chemical which seems to haveappeared first in 2020 or 2021, allefgedly first synthesized by either Skyler Ulrich or a chemist/group under the name of Gerstmann[citation needed], alongside other novel lysergamides like 1cP-AL-LAD on various research chemical markets.

User reports describe the effects of 1cP-MiPLA as similar to those of MiPLA. Some anecdotal reports state that there could be a notable, if even slight, difference between the two although this does not indicate that that it isn't a true prodrug for MiPLA. Many effects seem to be identical or nearly identical.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 1cP-MiPLA. While it is often characterized by users as being generally more recreational and non-threatening compared to LSD, it is highly advised to approach this highly potent hallucinogenic substance with the proper amount of precaution and harm reduction practices if using it.

Chemistry

1cP-MiPLA, or 1-Cyclopropionyl-N-nethyl-N-isopropyllysergamide, is a semisynthetic alkaloid of the lysergamide family. 1cP-MiPLA is a structural analog of lysergic acid, with an N-nethyl-N-isopropylamide functional group bound to RN of the chemical structure.

1cP-MiPLA's chemical structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid). It is substituted at R1 with a Cyclopropionyl substituent. At carbon 8 of the quinoline a N,N-diethyl carboxamide is bound.

1cP-MiPLA is a chiral compound with two stereocenters at R5 and R8. 1cP-MiPLA, also called (+)-D-1cP-MiPLA , has an absolute configuration of (5R, 8R). The three other stereoisomers of 1cP-MiPLA presumably do not have psychoactive properties.[citation needed]

Pharmacology

Further information: Serotonergic psychedelic

1cP-MiPLA likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from 1cP-MiPLA's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.

1cP-MiPLA is also suspected to be a prodrug for MiPLA, given it's 1-Cyclopropionyl substitution. This can be compared with 1cP-LSD, which is also likely a prodrug for LSD. However there is not enough data, anecdotes or guaratees that this will be the exacr same property of 1cP-MiPLA.

1cP-MiPLA also shares many common traits with its parent compound LSD; in humans it appears to be roughly equal (or less) in potency as well as similar in mechanism although the progression and duration of effects are compressed (while remaining qualitatively less intense and more manageable - perhaps due to being catabolised more readily). It is also notably less potent.

Subjective effects

While its subjective effects largely overlap with those of MiPLA and less so LSD, 1cP-MiPLA is commonly reported to be significantly shorter in its duration and less uncomfortable in both its negative physical side effects and general anxiety.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
Child.svg

Visual effects
Eye.svg

Transpersonal effects
Infinity4.svg

Combination effects

  • Alcohol - Alcohol's central depressant effects can counteract some of the anxiety and bodily tension produced by 1cP-MiPLA. However, alcohol can cause dehydration, nausea and physical fatigue which can negatively impact the tone of the trip. Users are advised to pace themselves and drink a portion of their usual amount.
  • Benzodiazepines - Benzodiazepines are highly effective at reducing the intensity of 1cP-MiPLA's effects through the general suppression of brain activity.
  • Cannabis - Cannabis strongly intensifies the sensory and cognitive effects of 1cP-MiPLA. Extreme caution is advised when using this combination as it can significantly increase the chances of a negative psychological reaction like anxiety, confusion and psychosis. Users are advised to start off with only a fraction of their usual cannabis dose and take long breaks between hits to avoid over intake.
  • Dissociatives - 1cP-MiPLA enhances the cognitive, visual and general hallucinatory effects of dissociatives. Dissociative-induced holes, spaces, and voids and internal hallucinations become more vivid and intense on 1cP-MiPLA. These effects correspond with an increased risk of confusion, delusions, and psychosis.
  • MDMA - 1cP-MiPLA and MDMA are highly synergistic and mutually enhance each other's physical, cognitive, and visual effects. The synergy between these substances is unpredictable so it is advised to start with markedly lower doses than one would take for each individually. There is some evidence that suggests that co-administration of LSD with MDMA increases the neurotoxicity of the latter,[1][2][3] and this may extend to 1cP-MiPLA.

Experience reports

There are currently 0 anecdotal reports which describe the effects of this compound within our experience index.

Toxicity and harm potential

Ambulance2.png

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

The toxicity and long-term health effects of recreational 1cP-MiPLA use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 1cP-MiPLA is a research chemical with very little history of human usage.

The body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

As with other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute 1cP-MiPLA exposure. Although no formal studies have been conducted, it is likely that as with LSD itself, 1cP-MiPLA is able to be considered non-addictive, with an extremely low toxicity relative to dose.[4] It is also likely that as with LSD, there are little to no negative physical, cognitive, psychiatric or other toxic consequences associated with acute 1cP-MiPLA exposure.

However, as with LSD and psychedelics in general, it is possible that 1cP-MiPLA can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.

It is strongly recommended that one uses harm reduction practices when using this substance.

Dependence and abuse potential

Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, 1cP-MiPLA is not habit-forming and that the desire to use it can actually decrease with use.

Tolerance to the effects of 1cP-MiPLA is built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). 1cP-MiPLA presents cross-tolerance with all psychedelics, meaning that after the use of 1cP-MiPLA all psychedelics will have a reduced effect.

Overdose

The LD50 of 1cP-MiPLA is unknown. Adverse psychological reactions are common especially at higher dosages. Some of these include anxiety, delusions, panic attacks and more rarely seizures. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the negative cognitive effects of 1cP-MiPLA.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous or even life-threatening when combined with certain other substances. The following lists some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status

1cP-MiPLA is currently a gray area compound within many parts of the world. This means that it is not known to be specifically illegal within most countries, but people may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.

  • Austria: 1cP-MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.[citation needed]
  • Germany: 1cP-MiPLA is illegal in Germany as of July 2021.[citation needed]
  • Switzerland: 1cP-MiPLA can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.[6]
  • United States: 1cP-MiPLA is unscheduled but can be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.[citation needed]

See also

External links

References

  1. Armstrong, B. D.; Paik, E.; Chhith, S.; Lelievre, V.; Waschek, J. A.; Howard, S. G. (2004). "Potentiation of (DL)‐3,4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptior partial agonist d‐lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939". Neuroscience Research Communications. 35 (2): 83–95. doi:10.1002/nrc.20023. ISSN 1520-6769. 
  2. Gudelsky, Gary A.; Yamamoto, Bryan; Nash, J. Frank (1994). "Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists". European Journal of Pharmacology. 264 (3): 325–330. doi:10.1016/0014-2999(94)90669-6. ISSN 0014-2999. 
  3. Capela, J. P.; Fernandes, E.; Remião, F.; Bastos, M. L.; Meisel, A.; Carvalho, F. (2007). "Ecstasy induces apoptosis via 5-HT2A-receptor stimulation in cortical neurons". Neurotoxicology. 28 (4): 868–875. doi:10.1016/j.neuro.2007.04.005. ISSN 0161-813X. PMID 17572501. 
  4. Passie, T.; Halpern, J. H.; Stichtenoth, D. O.; Emrich, H. M.; Hintzen, A. "The Pharmacology of Lysergic Acid Diethylamide: A Review" (PDF). CNS Neuroscience & Therapeutics. 14: 295–314. doi:10.1111/j.1755-5949.2008.00059.x. ISSN 1755-5930. Archived from the original (PDF) on May 1, 2013. Retrieved January 1, 2020. 
  5. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  6. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel,psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien: Änderung vom 2. November 2015" (PDF) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.